生物製剤の受託製造市場：製品、プラットフォーム、治療領域、事業規模別-2025-2030年の世界予測

生物製剤の受託製造市場は、2023年に228億2,000万米ドルと評価され、2024年には265億3,000万米ドルに達すると予測され、CAGR 16.74％で成長し、2030年には674億4,000万米ドルに達すると予測されています。

生物製剤の受託製造は、生物学的プロセスを通じて生産されるタンパク質、核酸、細胞などの複雑な分子である生物製剤の生産プロセスのアウトソーシングを包含しています。この産業は、専門施設に多額の設備投資をすることなく効率的に生産規模を拡大しようとする製薬会社やバイオテクノロジー企業にとって極めて重要です。生物製剤の用途は、腫瘍学、ワクチン、自己免疫疾患など様々な治療分野に及び、ヒトと動物両方の健康に貢献しています。契約製造業者は、細胞培養、発酵、精製、分析試験などの分野で専門知識を提供し、重要なパートナーとしての役割を果たしています。生物製剤の受託製造の必要性は、生物製剤に対する需要の高まり、バイオテクノロジーの進歩、コストや生産能力の問題を管理するための生産における柔軟性の必要性から生じています。主な市場成長要因としては、慢性疾患の有病率の上昇、個別化医療の採用の増加、シングルユースシステムや連続製造などの製造プロセスにおける技術進歩などが挙げられます。市場のビジネスチャンスは、サービス提供の多様化、新興国市場での拡大、バイオシミラー開発における協業に結びついています。しかし、厳しい規制要件、初期投資コストの高さ、高度に熟練した技術的専門知識の必要性などの課題が成長を抑制する可能性があります。さらに、潜在的なサプライチェーンの混乱や品質管理の問題が、さらなるハードルとなっています。革新的な分野としては、高度な細胞・遺伝子治療製造技術の開発、プロセス分析技術の改善、環境への影響を最小限に抑える持続可能な製造プロセスなどが挙げられます。市場は、急速な技術の進歩と規制状況の変化によりダイナミックに動いています。ビジネスチャンスを生かすため、企業は戦略的パートナーシップの促進、技術のアップグレードへの投資、エンド・ツー・エンドのソリューションをカバーするサービス・ポートフォリオの拡充に注力すべきです。規制要件を包括的に理解し、強固な品質管理システムを構築することは、市場の複雑性を乗り越え、持続可能な成長を実現する上で極めて重要です。

市場力学：急速に進化する生物製剤の受託製造市場の主要市場インサイトを公開

生物製剤の受託製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • バイオシミラーとワクチン製造に対する需要の増加
  • CMOによる生産能力拡大のための継続的な投資活動
  • 受託サービスによるコストや時間の節約などの主な利点
• 市場抑制要因
  • 各国間の貿易政策の変化
• 市場機会
  • シングルユースバイオプロセシング機器とソリューションの出現
  • 標的治療のための細胞・遺伝子治療への需要の高まり
• 市場の課題
  • 知的財産や特許の侵害に対する懸念

ポーターの5つの力：生物製剤の受託製造市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生物製剤の受託製造市場における外部からの影響の把握

外部マクロ環境要因は、生物製剤の受託製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生物製剤の受託製造市場における競合情勢の把握

生物製剤の受託製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生物製剤の受託製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生物製剤の受託製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生物製剤の受託製造市場における成功への道筋を描く

生物製剤の受託製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオシミラーとワクチン生産の需要増加
    • CMOによる生産能力拡大に向けた継続的な投資活動
    • 契約サービスによって得られるコストと時間の節約などの主要な利点
  • 抑制要因
    • 国家間の貿易政策の変化
  • 機会
    • 使い捨てバイオプロセス機器とソリューションの登場
    • 標的治療のための細胞・遺伝子治療の需要増加
  • 課題
    • 知的財産権と特許の侵害に対する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 生物製剤の受託製造市場：製品別

• バイオシミラー
• インスリン
• インターフェロン
• モノクローナル抗体
• 組み換えホルモン
• ワクチン

第7章 生物製剤の受託製造市場：プラットフォーム別

• 哺乳類
• 微生物

第8章 生物製剤の受託製造市場治療領域別

• 自己免疫疾患
• 心血管疾患
• 感染症
• 代謝性疾患
• 神経学
• 腫瘍学
• 眼科
• 呼吸器疾患

第9章 生物製剤の受託製造市場事業規模別

• 臨床
• 商業用

第10章 南北アメリカの生物製剤の受託製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の生物製剤の受託製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの生物製剤の受託製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Abzena Ltd.
• Acino International AG
• ADMA Biologics, Inc.
• AGC Biologics
• Ajinomoto Bio-Pharma Services
• Avid Bioservices, Inc.
• Baxter International, Inc
• Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
• Cambrex Corporation
• Catalent, Inc.
• Emergent BioSolutions, Inc.
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
• JSR Life Sciences, LLC by JSR Group
• Kemwell Biopharma Pvt. Ltd.
• Lonza Group Ltd.
• Midas Pharma GmbH
• ProBioGen AG
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• Thermo Fisher Scientific, Inc.
• Toyobo Co. Ltd.
• Wacker Chemie AG
• WuXi Biologics Co., Ltd.

LIST OF FIGURES

• FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOLOGICS CONTRACT MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 44. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 45. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 66. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 67. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 70. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 71. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 75. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 79. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 83. MALAYSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 87. PHILIPPINES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 91. SINGAPORE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 99. TAIWAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 103. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 107. VIETNAM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 116. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 120. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 124. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 128. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 132. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 136. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 139. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 140. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 144. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 148. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 152. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 154. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 155. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 156. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 159. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 160. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 164. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 168. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 176. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 180. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 184. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 188. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 192. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 196. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
• TABLE 197. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 198. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Biologics Contract Manufacturing Market was valued at USD 22.82 billion in 2023, expected to reach USD 26.53 billion in 2024, and is projected to grow at a CAGR of 16.74%, to USD 67.44 billion by 2030.

Biologics contract manufacturing encompasses the outsourcing of production processes for biologics-complex molecules such as proteins, nucleic acids, or cells produced through biological processes. This industry is crucial for pharmaceutical and biotech companies seeking to scale production efficiently without significant capital investment in specialized facilities. The application of biologics spans various therapeutic areas, including oncology, vaccines, and autoimmune diseases, catering to both human and veterinary health. Contract manufacturers serve as key partners, offering expertise in areas such as cell culture, fermentation, purification, and analytical testing. The necessity for biologics contract manufacturing arises from the growing demand for biologics, advancements in biotechnology, and the need for flexibility in production to manage costs and capacity issues. Key market growth factors include the rising prevalence of chronic diseases, increasing adoption of personalized medicine, and technological advancements in manufacturing processes, such as single-use systems and continuous manufacturing. Opportunities in the market are tied to the diversification of service offerings, expansion in emerging markets, and collaboration on biosimilar development. However, challenges such as stringent regulatory requirements, high initial investment costs, and the need for highly skilled technical expertise can restrain growth. Furthermore, potential supply chain disruptions and quality control issues present additional hurdles. Innovation areas include the development of advanced cell and gene therapy manufacturing techniques, improvements in process analytical technologies, and sustainable manufacturing processes to minimize environmental impact. The market is dynamic, driven by rapid technological advancements and shifting regulatory landscapes. To capitalize on opportunities, companies should focus on fostering strategic partnerships, investing in technology upgrades, and expanding service portfolios to cover end-to-end solutions. A comprehensive understanding of regulatory requirements and a robust quality management system are crucial to navigating market complexities and achieving sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Manufacturing Market

The Biologics Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing demand for biosimilars and vaccine production
  • Ongoing investment activities by CMOs for capacity expansion
  • Key advantages such as cost and time saving offered by contract services
• Market Restraints
  • Changing trade policies between countries
• Market Opportunities
  • Emergence of single-use bioprocessing equipment & solutions
  • Rising demand for cell and gene therapies for targeted treatment
• Market Challenges
  • Concerns over the breach of intellectual property and patents

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Manufacturing Market

A detailed market share analysis in the Biologics Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Manufacturing Market

A strategic analysis of the Biologics Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Acino International AG, ADMA Biologics, Inc., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Baxter International, Inc, Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Midas Pharma GmbH, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., Wacker Chemie AG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines.
• Based on Platform, market is studied across Mammalian and Microbial.
• Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.
• Based on Scale of Operation, market is studied across Clinical and Commercial.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for biosimilars and vaccine production
    • 5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
    • 5.1.1.3. Key advantages such as cost and time saving offered by contract services
  • 5.1.2. Restraints
    • 5.1.2.1. Changing trade policies between countries
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
    • 5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns over the breach of intellectual property and patents
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biologics Contract Manufacturing Market, by Product

• 6.1. Introduction
• 6.2. Biosimilar
• 6.3. Insulin
• 6.4. Interferons
• 6.5. Monoclonal Antibodies
• 6.6. Recombinant Hormones
• 6.7. Vaccines

7. Biologics Contract Manufacturing Market, by Platform

• 7.1. Introduction
• 7.2. Mammalian
• 7.3. Microbial

8. Biologics Contract Manufacturing Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Autoimmune Diseases
• 8.3. Cardiovascular Diseases
• 8.4. Infectious Diseases
• 8.5. Metabolic Diseases
• 8.6. Neurology
• 8.7. Oncology
• 8.8. Ophthalmology
• 8.9. Respiratory Disorders

9. Biologics Contract Manufacturing Market, by Scale of Operation

• 9.1. Introduction
• 9.2. Clinical
• 9.3. Commercial

10. Americas Biologics Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Biologics Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Biologics Contract Manufacturing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Abzena Ltd.
• 3. Acino International AG
• 4. ADMA Biologics, Inc.
• 5. AGC Biologics
• 6. Ajinomoto Bio-Pharma Services
• 7. Avid Bioservices, Inc.
• 8. Baxter International, Inc
• 9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
• 10. Cambrex Corporation
• 11. Catalent, Inc.
• 12. Emergent BioSolutions, Inc.
• 13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
• 14. JSR Life Sciences, LLC by JSR Group
• 15. Kemwell Biopharma Pvt. Ltd.
• 16. Lonza Group Ltd.
• 17. Midas Pharma GmbH
• 18. ProBioGen AG
• 19. Recipharm AB
• 20. Rentschler Biopharma SE
• 21. Samsung Biologics
• 22. Thermo Fisher Scientific, Inc.
• 23. Toyobo Co. Ltd.
• 24. Wacker Chemie AG
• 25. WuXi Biologics Co., Ltd.